Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/208722
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNadal, Ernest-
dc.contributor.authorRodríguez Abreu, Delvys-
dc.contributor.authorSimó, Marta-
dc.contributor.authorMassutí, Bartomeu-
dc.contributor.authorJuan, Oscar-
dc.contributor.authorHuidobro, Gerardo-
dc.contributor.authorLópez, Rafael-
dc.contributor.authorCastro, Javier de-
dc.contributor.authorEstival, Anna-
dc.contributor.authorMosquera, Joaquín-
dc.contributor.authorSullivan, Ivana-
dc.contributor.authorFelip, Enriqueta-
dc.contributor.authorBlasco, Ana-
dc.contributor.authorGuirado, Maria-
dc.contributor.authorPereira, Eva-
dc.contributor.authorVilariño, Noelia-
dc.contributor.authorNavarro, Valentín-
dc.contributor.authorBruna, Jordi-
dc.date.accessioned2024-03-13T11:09:40Z-
dc.date.available2024-03-13T11:09:40Z-
dc.date.issued2023-10-01-
dc.identifier.issn1527-7755-
dc.identifier.urihttp://hdl.handle.net/2445/208722-
dc.description.abstractPURPOSEThe Atezo-Brain study evaluated atezolizumab combined with chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) with untreated brain metastases, a population traditionally excluded from trials.METHODSThis single-arm phase II clinical trial enrolled patients with advanced nonsquamous NSCLC with untreated brain metastases without neurologic symptoms or asymptomatic with medical treatment. Dexamethasone was allowed up to 4 mg once daily. Atezolizumab plus carboplatin and pemetrexed was given for four to six cycles followed by atezolizumab plus pemetrexed until progression for a maximum of 2 years. The primary end points were to determine the progression-free survival (PFS) rate at 12 weeks and the incidence of grade >= 3 adverse events during the first 9 weeks. Intracranial outcomes were assessed using response assessment in neuro-oncology brain metastases criteria.RESULTSForty patients were enrolled and 22 (55%) were receiving corticosteroids at baseline. The overall 12-week PFS rate was 62.2% (95% credibility interval [CrI], 47.1 to 76.2). The rate of grade 3/4 adverse events during the first 9 weeks was 27.5%. Most neurologic events were grade 1 and 2 but five patients (12.5%) experienced grade 3-4 neurologic events. With a median follow-up of 31 months, intracranial median PFS was 6.9 months and response rate was 42.7% (95% CrI, 28.1 to 57.9). Systemic median PFS was 8.9 months and response rate was 45% (95% CrI, 28.1 to 57.9). The median overall survival (OS) was 11.8 months (95% CI, 7.6 to 16.9) and the 2-year OS rate was 27.5% (95% CI, 16.6 to 45.5).CONCLUSIONAtezolizumab plus carboplatin and pemetrexed demonstrates activity in patients with advanced nonsquamous NSCLC with untreated brain metastases with an acceptable safety profile.-
dc.format.extent10 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherAmerican Society of Clinical Oncology (ASCO)-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1200/JCO.22.02561-
dc.relation.ispartofJournal of Clinical Oncology, 2023, vol. 41, num. 28, p. 4478-4485-
dc.relation.urihttps://doi.org/10.1200/JCO.22.02561-
dc.rightscc by-nc-nd (c) American Society of Clinical Oncology (ASCO), 2023-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationTumors cerebrals-
dc.subject.classificationCàncer de pulmó-
dc.subject.otherBrain tumors-
dc.subject.otherLung cancer-
dc.titlePhase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2023-11-28T09:31:27Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid37603816-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
nadal-et-al-2023-phase-ii-trial-of-atezolizumab-combined.pdf778.44 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons